Clinical Trial: NCT04071223
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-09-28 |
Study Overview
Brief Summary
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
Official Title
Conditions
Intervention / Treatment
- Procedure: Biospecimen Collection
- Procedure: Bone Scan
- Drug: Cabozantinib S-malate
- Procedure: Computed Tomography
- Procedure: Magnetic Resonance Imaging
- Procedure: Positron Emission Tomography
- Other: Questionnaire Administration
- Radiation: Radium Ra 223 Dichloride
Other Study ID Numbers
- NCI-2019-05619
- NCI-2019-05619
- A031801
- A031801
- U10CA180821
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-09-28 |
Study Overview
Brief Summary
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
Official Title
Conditions
Intervention / Treatment
- Procedure: Biospecimen Collection
- Procedure: Bone Scan
- Drug: Cabozantinib S-malate
- Procedure: Computed Tomography
- Procedure: Magnetic Resonance Imaging
- Procedure: Positron Emission Tomography
- Other: Questionnaire Administration
- Radiation: Radium Ra 223 Dichloride
Other Study ID Numbers
- NCI-2019-05619
- NCI-2019-05619
- A031801
- A031801
- U10CA180821